Prognostic Value of the De Ritis Ratio for Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [(177)Lu]Lu-PSMA-617 Radioligand Therapy

SIMPLE SUMMARY: Radioligand therapy with [(177)Lu]Lu-PSMA-617 is an effective treatment for patients with prostate cancer. However, survival after radioligand therapy differs widely because patients respond differently to treatment but also enter therapy with an individual set of risk factors. We re...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaal, Sebastian, Huang, Kai, Rogasch, Julian M. M., Jochens, Hans V., De Santis, Maria, Erber, Barbara, Amthauer, Holger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605155/
https://www.ncbi.nlm.nih.gov/pubmed/37894274
http://dx.doi.org/10.3390/cancers15204907

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605155/
https://www.ncbi.nlm.nih.gov/pubmed/37894274
http://dx.doi.org/10.3390/cancers15204907

Ejemplares similares